Veracyte, Inc.
VCYT
$46.41
$0.140.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 561.90M | 541.74M | 517.15M | 495.14M | 479.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 561.90M | 541.74M | 517.15M | 495.14M | 479.13M |
| Cost of Revenue | 150.75M | 149.60M | 146.77M | 148.37M | 143.84M |
| Gross Profit | 411.15M | 392.15M | 370.37M | 346.77M | 335.29M |
| SG&A Expenses | 211.32M | 213.11M | 220.54M | 214.98M | 211.97M |
| Depreciation & Amortization | 13.11M | 13.23M | 13.15M | 13.43M | 13.90M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 468.55M | 456.14M | 451.28M | 446.03M | 440.55M |
| Operating Income | 93.35M | 85.61M | 65.87M | 49.11M | 38.58M |
| Income Before Tax | 116.02M | 90.75M | 68.20M | 31.01M | 28.97M |
| Income Tax Expenses | 1.54M | 2.73M | 1.85M | 693.00K | 2.63M |
| Earnings from Continuing Operations | 114.48 | 88.01 | 66.35 | 30.32 | 26.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 114.48M | 88.01M | 66.35M | 30.32M | 26.34M |
| EBIT | 93.35M | 85.61M | 65.87M | 49.11M | 38.58M |
| EBITDA | 114.18M | 107.09M | 87.28M | 71.48M | 61.56M |
| EPS Basic | 1.44 | 1.11 | 0.84 | 0.39 | 0.34 |
| Normalized Basic EPS | 0.87 | 0.83 | 0.66 | 0.49 | 0.43 |
| EPS Diluted | 1.40 | 1.08 | 0.82 | 0.38 | 0.33 |
| Normalized Diluted EPS | 0.85 | 0.82 | 0.65 | 0.49 | 0.43 |
| Average Basic Shares Outstanding | 317.41M | 315.83M | 314.32M | 312.75M | 311.04M |
| Average Diluted Shares Outstanding | 324.45M | 320.78M | 319.53M | 318.04M | 316.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |